Wall Street Giants Battle a Secret Deal Whisperer on Tech IPOs

In This Article:

(Bloomberg) -- When Pagerduty Inc. hired investment banks for its initial public offering earlier this year, Morgan Stanley turned the conversation to another possible outcome: a sale of the startup. The Wall Street giant wanted to make sure it would still be an adviser if Pagerduty ended up getting acquired instead of listing on the New York Stock Exchange as planned.

Morgan Stanley’s bid for reassurance was driven in part by an increasing threat from boutique investment banks, in particular Frank Quattrone’s Qatalyst Partners, which have become adept at finding acquisition deals for technology companies in the final stages of IPOs. That means big fees for Qatalyst and other boutiques such as Centerview Partners, and higher rankings on league tables that measure banking clout. Meanwhile, Morgan Stanley and bulge-bracket peers such as Goldman Sachs Group Inc. and JPMorgan Chase & Co. risk being left with no reward after months of work prepping companies for public listings.

Boutique firms don’t pull this off regularly, and they still advise on far fewer deals. But they’ve done enough to unsettle Wall Street’s largest firms. Morgan Stanley and other IPO underwriters are now asking some clients for reassurances that the banks will still be included – and paid – as advisers even if listings fall through in favor of acquisitions, according to people familiar with the situation. Qatalyst and Morgan Stanley declined to comment.

These requests typically take the form of a handshake agreement, said the people, who asked not to be identified discussing private negotiations. But sometimes the pacts are written into underwriting agreements. The chief executive officer of a startup that held one of last year’s most-successful IPOs said he signed one of these clauses because he planned to stick to the IPO and believed an acquisition was a moot issue. Morgan Stanley underwrote that offering. With more venture-backed companies set to list soon -- including cybersecurity firm CrowdStrike, customer-feedback company Medallia, and data-management startup Rubrik – millions of dollars in banking fees are at stake.

It’s not only Morgan Stanley that is losing out. Biotech company Peloton Therapeutics Inc. was acquired by Merck & Co. for as much as $2.2 billion on the eve of its IPO earlier this month. Peloton tapped Centerview for M&A advice. It’s unclear whether the three IPO underwriters, J.P. Morgan, Citigroup Inc. and Jefferies Financial Group Inc., were involved in the purchase negotiations. At least one of these banks got no fees for their work. The banks declined to comment.